Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

MRI of a patient with a glioblastoma tumor. Photo: BSIP/UIG via Getty Images

An international team of scientists say they've developed a molecule that can target the two most common brain cancers, successfully slowing down tumor growth in a pre-clinical study on animals published in Nature Wednesday.

Why it matters: The targeted brain cancers — adults' glioblastoma and children's medulloblastoma — are aggressive cancers often fatal within 2 years (as seen when glioblastoma claimed the life of Sen. John McCain). This team hopes this new method, which successfully breaches the blood-brain barrier, may be an important step forward in finding an effective treatment.

Background: Glioblastoma and medulloblastoma tumors are often deep in the brain where it's difficult to surgically remove them. Immunotherapies are thought by many to offer great promise in treating the tumors, but they face many challenges, including safely breaching the blood-brain barrier.

The barrier offers important protection for the brain, but can keep out drugs that doctors want to send to the brain to trigger the body's own immune system to fight the cancer.

What they did: The team first determined the best way to breach the brain barrier by studying the mechanism used by another disease, multiple sclerosis, to get around the barrier.

  • Then, "using lessons learned from MS," they developed a molecule that can get around the barrier by attaching to certain cells of the barrier (known as ALCAM), study co-author Nabil Ahmed tells Axios.
  • The T-cells are engineered to bind to an antigen produced by the cancer (called HER2), allowing it to locate and attack the tumors.

What they found: In testing in mice, the molecule, known as HS-CD6, "robustly infiltrated brain cancers after intravenous injection and exhibited potent antitumor activity," the study states.

  • The therapy did not appear to be toxic, which is a common failing of immunotherapies, as the mice lived longer. In addition, the therapy appeared to only attack the tumor sites, the authors said.
"The HS molecule that can overcome this [blood-brain] obstacle is a first-in-class; no similar molecules have been previously described. ... I am quite excited about the possible advantage of this to patients with incurable brain cancers that could hopefully benefit from using this in the clinic."
— Nabil Ahmed, Baylor College of Medicine

Outside comment: Two experts not involved with the study say these results show promise, but are a first step towards a bigger goal.

"This study represents a major leap forward in our understanding of [trafficking T cells] to brain tumors... Engineering T cells to overcome mechanistic barriers to tumor infiltration, the authors demonstrate a marked increase in tumor-infiltrating lymphocytes and increased efficacy of a [CAR-T] cell therapy. This is an elegant study with exciting implications for therapy of these lethal cancers." 
— Michelle Monje-Deisseroth, associate professor of neurology, Stanford University
"This study lays out a viable strategy for immunotherapy in glioblastoma. But key challenges must be overcome before we can translate the discovery from mice to patients. For instance, ALCAM is expressed by a variety of cell types, including bone-marrow cells. More studies will be required."
— Michael Platten, of Heidelberg University, in a News and Views piece in Nature

What's next: Ahmed tells Axios they are currently working on securing approvals from regulatory bodies to test this on humans with hard-to-treat or incurable brain cancers.

Go deeper: Read the National Cancer Institute's in-depth look at challenges facing glioblastoma and immunotherapy.

Go deeper

2 hours ago - Health

Prior coronavirus infections may not protect well against Omicron

Illustration: Aïda Amer/Axios

New data from South Africa suggests the Omicron variant spreads more than twice as quickly as the Delta variant, and that immunity from prior infection doesn't appear to protect a person very well against Omicron variant.

Why it matters: The findings are extremely preliminary, and there are still many open questions about how well vaccines work against the variant. But these initial breadcrumbs of data are helping the world begin to understand what it's up against.

Bryan Walsh, author of Future
2 hours ago - Technology

AI could end foreign-language subtitles

Illustration: Shoshana Gordon/Axios

AI companies are developing methods to translate and synthesize voices in ads, movies and TV.

Why it matters: The advances in voice synthesis could help fix bad movie dubbing — and they come as international content is becoming increasingly important to studios and streaming platforms as part of the globalization of entertainment.

Bryan Walsh, author of Future
Updated 11 hours ago - Technology

A dark view of the future of autonomous weapons

A still from the video "If Human: Kill ( )." Image: Future of Life Institute

A new short film warns of the coming risks posed by the development and proliferation of lethal autonomous weapons.

Why it matters: Drones with the ability to autonomously target and kill without the assistance of a human operator are reportedly already being used on battlefields, and time is running out to craft a global ban of what could be a destabilizing and terrifying new class of weapon.